S&P 500   4,967.23
DOW   37,986.40
QQQ   417.45
Lithium Overdose: Can These 2 Lithium Stocks Recover in 2024?
North Carolina medical marijuana sales begin at Cherokee store
'Civil War’ continues box-office campaign at No. 1
Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?
Intuitive Surgical Leads the Robotic Surgery Movement
Stock market today: Wall Street eyes corporate earnings after last week's Big Tech selloff
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
S&P 500   4,967.23
DOW   37,986.40
QQQ   417.45
Lithium Overdose: Can These 2 Lithium Stocks Recover in 2024?
North Carolina medical marijuana sales begin at Cherokee store
'Civil War’ continues box-office campaign at No. 1
Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?
Intuitive Surgical Leads the Robotic Surgery Movement
Stock market today: Wall Street eyes corporate earnings after last week's Big Tech selloff
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
S&P 500   4,967.23
DOW   37,986.40
QQQ   417.45
Lithium Overdose: Can These 2 Lithium Stocks Recover in 2024?
North Carolina medical marijuana sales begin at Cherokee store
'Civil War’ continues box-office campaign at No. 1
Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?
Intuitive Surgical Leads the Robotic Surgery Movement
Stock market today: Wall Street eyes corporate earnings after last week's Big Tech selloff
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
S&P 500   4,967.23
DOW   37,986.40
QQQ   417.45
Lithium Overdose: Can These 2 Lithium Stocks Recover in 2024?
North Carolina medical marijuana sales begin at Cherokee store
'Civil War’ continues box-office campaign at No. 1
Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?
Intuitive Surgical Leads the Robotic Surgery Movement
Stock market today: Wall Street eyes corporate earnings after last week's Big Tech selloff
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
NYSE:MED

Medifast (MED) Stock Price, News & Analysis

$32.44
-0.03 (-0.09%)
(As of 04/19/2024 06:40 PM ET)
Today's Range
$32.11
$32.99
50-Day Range
$31.35
$56.23
52-Week Range
$30.95
$109.52
Volume
288,400 shs
Average Volume
382,055 shs
Market Capitalization
$353.60 million
P/E Ratio
3.56
Dividend Yield
N/A
Price Target
$61.00

Medifast MarketRank™ Stock Analysis

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
88.0% Upside
$61.00 Price Target
Short Interest
Bearish
25.09% of Float Sold Short
Dividend Strength
N/A
Sustainability
-4.07
Upright™ Environmental Score
News Sentiment
0.13mentions of Medifast in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$159,850 Sold Last Quarter
Proj. Earnings Growth
40.45%
From $3.56 to $5.00 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.83 out of 5 stars

Consumer Staples Sector

54th out of 134 stocks

Miscellaneous Food Preparations & Kindred Products Industry

2nd out of 4 stocks

MED stock logo

About Medifast Stock (NYSE:MED)

Medifast, Inc., through its subsidiaries, engages in the manufacture and sale of weight loss, weight management, and healthy living products in the United States and the Asia-Pacific. It offers bars, puffs, cereal, crunchers, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups under the OPTAVIA, OPTAVIA ACTIVE, and Optimal Health brand names. The company markets its products through point-of-sale transactions, as well as through ecommerce platform. Medifast, Inc. was founded in 1980 and is headquartered in Baltimore, Maryland.

MED Stock Price History

MED Stock News Headlines

Medifast (MED) to Release Quarterly Earnings on Monday
The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
(MED) - Analyzing Medifast's Short Interest
Medifast: Cheap Valuation, Uncertain Future
MED Apr 2024 20.000 put
LifeMD, Inc.: LifeMD Reports Fourth Quarter 2023 Results
MED Jun 2024 52.500 call
Medifast Is Getting Attractive
See More Headlines
Receive MED Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Medifast and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/20/2024
Today
4/22/2024
Next Earnings (Confirmed)
4/29/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Industry
Miscellaneous food preparations & kindred products
Sub-Industry
Personal Products
CUSIP
58470H10
Employees
634
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$61.00
High Stock Price Target
$82.00
Low Stock Price Target
$40.00
Potential Upside/Downside
+88.0%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
2 Analysts

Profitability

Net Income
$99.42 million
Pretax Margin
12.01%

Debt

Sales & Book Value

Annual Sales
$1.07 billion
Cash Flow
$10.85 per share
Book Value
$18.50 per share

Miscellaneous

Free Float
10,672,000
Market Cap
$353.60 million
Optionable
Optionable
Beta
1.14
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Mr. Daniel R. ChardMr. Daniel R. Chard (Age 59)
    Executive Chairman & CEO
    Comp: $1.94M
  • Mr. James P. Maloney CPA (Age 56)
    Chief Financial Officer
    Comp: $823.91k
  • Mr. Anthony E. Tyree (Age 59)
    Chief Business Operations Officer
    Comp: $655.86k
  • Mr. Jason L. Groves Esq. (Age 53)
    Executive VP, General Counsel & Corporate Secretary
    Comp: $669.51k
  • Mr. Nicholas M. Johnson (Age 44)
    Chief Field Operations Officer
    Comp: $696.4k
  • Mr. Jonathan Barrett MacKenzie (Age 52)
    VP of Finance & Chief Accounting Officer
  • Mr. Steven Zenker
    Vice President of Investor Relations
  • Ms. Claudia C. Greninger (Age 51)
    Chief Human Resources Officer

MED Stock Analysis - Frequently Asked Questions

Should I buy or sell Medifast stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Medifast in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" MED shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MED, but not buy additional shares or sell existing shares.
View MED analyst ratings
or view top-rated stocks.

What is Medifast's stock price target for 2024?

2 brokerages have issued 12 month price targets for Medifast's shares. Their MED share price targets range from $40.00 to $82.00. On average, they predict the company's stock price to reach $61.00 in the next twelve months. This suggests a possible upside of 88.0% from the stock's current price.
View analysts price targets for MED
or view top-rated stocks among Wall Street analysts.

How have MED shares performed in 2024?

Medifast's stock was trading at $67.22 on January 1st, 2024. Since then, MED shares have decreased by 51.7% and is now trading at $32.44.
View the best growth stocks for 2024 here
.

Are investors shorting Medifast?

Medifast saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 2,660,000 shares, an increase of 29.8% from the March 15th total of 2,050,000 shares. Based on an average daily volume of 384,900 shares, the days-to-cover ratio is currently 6.9 days. Approximately 25.1% of the company's shares are short sold.
View Medifast's Short Interest
.

When is Medifast's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, April 29th 2024.
View our MED earnings forecast
.

How can I listen to Medifast's earnings call?

Medifast will be holding an earnings conference call on Monday, April 29th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link or dial in at 844-512-2921 with passcode "13745406".

How were Medifast's earnings last quarter?

Medifast, Inc. (NYSE:MED) announced its quarterly earnings results on Tuesday, February, 20th. The specialty retailer reported $1.09 EPS for the quarter, topping analysts' consensus estimates of $0.99 by $0.10. The specialty retailer earned $191.02 million during the quarter, compared to analysts' expectations of $184.17 million. Medifast had a net margin of 9.27% and a trailing twelve-month return on equity of 56.06%. Medifast's revenue was down 43.4% on a year-over-year basis. During the same period in the previous year, the firm posted $3.70 earnings per share.

How often does Medifast pay dividends? What is the dividend yield for Medifast?

Medifast announced a quarterly dividend on Thursday, September 7th. Shareholders of record on Tuesday, September 19th will be paid a dividend of $1.65 per share on Tuesday, November 7th. This represents a $6.60 annualized dividend and a yield of 20.35%. The ex-dividend date is Monday, September 18th.
Read our dividend analysis for MED
.

What ETFs hold Medifast's stock?
What guidance has Medifast issued on next quarter's earnings?

Medifast updated its first quarter 2024 earnings guidance on Tuesday, February, 20th. The company provided EPS guidance of 0.250-0.950 for the period, compared to the consensus earnings per share estimate of 1.490. The company issued revenue guidance of $155.0 million-$175.0 million, compared to the consensus revenue estimate of $205.8 million.

What is Daniel Chard's approval rating as Medifast's CEO?

44 employees have rated Medifast Chief Executive Officer Daniel Chard on Glassdoor.com. Daniel Chard has an approval rating of 93% among the company's employees. This puts Daniel Chard in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Medifast own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Medifast investors own include NVIDIA (NVDA), Alibaba Group (BABA), AbbVie (ABBV), Home Depot (HD), Boeing (BA), Johnson & Johnson (JNJ), Intel (INTC), Cisco Systems (CSCO), AT&T (T) and Exxon Mobil (XOM).

Who are Medifast's major shareholders?

Medifast's stock is owned by a variety of institutional and retail investors. Top institutional investors include Allspring Global Investments Holdings LLC (0.39%), Denali Advisors LLC (0.24%), Chickasaw Capital Management LLC (0.17%), DGS Capital Management LLC (0.10%), Aviance Capital Partners LLC (0.08%) and Rowlandmiller & PARTNERS.ADV (0.03%). Insiders that own company stock include Andrea B Thomas, Constance J Hallquist, Constance J Hallquist, Daniel R Chard, Jeffrey J Brown, Jeffrey J Brown, Kevin G Byrnes and Scott Schlackman.
View institutional ownership trends
.

How do I buy shares of Medifast?

Shares of MED stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:MED) was last updated on 4/22/2024 by MarketBeat.com Staff

From Our Partners